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Abstract: 
Rationale 
The pathophysiology of most lacunar stroke, a form of small vessel disease (SVD), is 
thought to differ from large artery atherothrombo- or cardio-embolic stroke. Licenced drugs, 
isosorbide mononitrate (ISMN) and cilostazol, have promising mechanisms of action to 
support their testing to prevent stroke recurrence, cognitive impairment or radiological 
progression after lacunar stroke. 
 
Aim  
LACI-1 will assess the tolerability, safety and efficacy, by dose, of ISMN and cilostazol, alone 
and in combination, in patients with ischaemic lacunar stroke.  
 
Sample size  
A sample of 60 provides 80+% power (significance 0.05) to detect a difference of 35% (90% 
versus 55%) between those reaching target dose on one versus both drugs. 
 
Methods and design 
LACI-1 is a phase IIa partial factorial, dose-escalation, prospective, randomised, open label, 
blinded endpoint (PROBE) trial. Participants are randomised to ISMN and/or cilostazol for 11 
weeks with dose escalation to target as tolerated in two centres (Edinburgh, Nottingham). At 
three visits, tolerability, safety, blood pressure, pulse wave velocity and platelet function are 
assessed, plus magnetic resonance imaging (MRI) to assess cerebrovascular reactivity in a 
subgroup. 
 
Study outcomes 
Primary: proportion of patients completing study achieving target maximum dose. 
 
Secondary: symptoms whilst taking medications; safety (haemorrhage, recurrent vascular 
events, falls); blood pressure, platelet function, arterial stiffness and cerebrovascular 
reactivity. 
 
Discussion 
This study will inform the design of a larger phase III trial of ISMN and cilostazol in lacunar 
stroke, whilst providing data on the drugs’ effects on vascular and platelet function. 
 
Trial Registration: ISRCTN (ISRCTN12580546) and EudraCT (2015-001953-33) 
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Introduction and rationale  
Cerebral small vessel disease (SVD) is a common disorder that affects small perforating 
arterioles in the brain’s deep white and grey matter.(1) It causes 25% of ischaemic strokes 
(‘lacunar’ stroke), intracerebral haemorrhage, vascular and many mixed dementias, gait and 
bladder dysfunction(1, 2). Cardioembolism and atherothromboembolism are uncommon in 
lacunar stroke and SVD. Although the pathophysiology remains poorly understood, 
endothelial dysfunction(1, 3, 4), inflammation(3, 5), blood-brain barrier failure(6) and 
impaired vasoreactivity(4, 7) have been demonstrated.  
There is no specific secondary prevention for lacunar stroke, SVD-associated dementia or 
progression of SVD lesions on neuroimaging(1). We recently summarised available drugs 
with potentially relevant  actions and identified two agents that seemed worthy of further 
testing: isosorbide mononitrate (ISMN) and cilostazol(8). 
ISMN, a nitric oxide (NO) donor, is commonly used in angina. NO levels are reduced in 
acute,(9) chronic (10) and possibly in lacunar stroke(11). NO has many potentially beneficial 
effects for SVD including improved vasoreactivity, neuroprotection and anti-inflammatory 
effects(8). In the Efficacy of Nitric Oxide in Stroke (ENOS) trial, the NO donor glyceryl 
trinitrate administered within six hours of all types of stroke, improved cognitive test scores at 
90 days (12). However, there are few data on ISMN in lacunar stroke in part because 
ischaemic heart disease, for which ISMN is licensed, is relatively infrequent in those with 
SVD(13).  
Cilostazol is a phosphodiesterase 3’ inhibitor(8), mainly used  for peripheral vascular disease 
in Europe and North America(14), but  more widely used for cerebrovascular disease 
prevention in Asia-Pacific countries. Cilostazol has mild antiplatelet effects plus several 
potentially beneficial effects for SVD including improved blood-brain barrier integrity, 
vasodilatory and anti-proliferative activity, improves oligodendrocyte maturation and hence 
myelination(15), and reduces white cell chemotaxis(8). In models it improved motor and 
cognitive function, and reduced infarct volume(16) and in human lacunar stroke it improved 
middle cerebral artery pulsatility index(17). Over 6000 patients, many with lacunar stroke, 
have been included in trials of cilostazol in secondary stroke prevention mostly in Asia-
Pacific countries (Fig. 1); a meta-analysis of these suggested that cilostazol reduces 
recurrent stroke(18-21).  
There is little experience of ISMN in lacunar stroke, cilostazol is rarely used for stroke 
prevention in Europe or the Americas. There are no data on the effects of cilostazol when 
combined with ISMN yet the effects are potentially synergistic(8).  
 
Therefore, the Lacunar Intervention Trial-1 (LACI-1) will test ISMN and cilostazol, alone and 
combined, in patients with lacunar ischaemic stroke, to assess their tolerability, safety and 
efficacy on mechanistic endpoints including cerebrovascular reactivity assessed using 
magnetic resonance imaging (MRI). Treatment will be given in addition to current guideline-
based post-stroke secondary prevention. LACI-1 will inform the design of a larger trial to test 
ISMN and cilostazol effects on recurrent vascular events, cognition, disability, death and 
SVD lesion progression on MRI (LACI-2).  LACI-1 was designed through a UK National 
Institute for Health Research Stroke Research Network Expert Writing Group.  
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Methods 
Design 
Phase IIa, partial factorial, dose-escalation, prospective, randomised, open label, blinded 
endpoint (PROBE) trial conducted in two UK centres (Edinburgh, Nottingham).  
Participants are randomised in a 1:1:1:1 ratio into four groups: cilostazol alone; ISMN alone; 
cilostazol and ISMN combined, started immediately (with ISMN given first); and cilostazol 
and ISMN combined, start delayed for three weeks (cilostazol first) (Fig. 2). The delayed 
start group also provides a ‘no drug’ comparison group during the first three weeks. 
Participants take trial medication for 11 weeks. The dose is increased, in weekly increments 
over 2-3 weeks as tolerated, sustained until 8 weeks post-randomisation, then decreased 
gradually over two weeks and stopped (Supplementary Information gives medication by 
study week). The escalating dose is designed to reduce potential adverse effects following 
initiation of cilostazol and is standard for ISMN. Gradual dose reduction aims to prevent 
large haemodynamic changes on cessation of medication. 
 
Patient population  
Inclusion: 
1. Mild symptomatic ischaemic lacunar stroke in the past four years, compatible with a 
clinical lacunar stroke syndrome, with brain MRI or CT scanning showing a 
symptomatic small subcortical (lacunar) infarct (<20mm), or if no recent relevant 
infarct is visible, that excluded other cause for symptoms. Clinical or imaging 
evidence of a prior non-lacunar stroke is not an exclusion as long as the randomising 
clinician is confident that the non-lacunar stroke is not responsible for the index 
lacunar stroke symptoms.  
2. Age ≥ 35 years  
3. Independent in activities of daily living (modified Rankin Scale of ≤2) and able to give 
informed consent. 
Exclusion: 
1. Other significant neurological illness since the incident stroke 
2. Age <35 years 
3. Montreal Cognitive Assessment (MoCA) <20 
4. Requiring assistance with activities of daily living (modified Rankin Scale ≥3) 
5. Active cardiac disease 
6. Carotid stenosis >50% (NASCET criteria) on the side of the symptomatic stroke 
lesion requiring urgent intervention. Note: successfully treated carotid artery stenosis 
may be included 
7. Definite indication for, or contraindication to, cilostazol or ISMN 
8. Unable to swallow 
9. Bleeding tendency 
10. Unlikely to comply with trial medication based on past history or lifestyle 
11. Planned surgery during the trial period 
12. History of intracranial haemorrhage (but not asymptomatic haemorrhagic 
transformation of an infarct) 
13. Other life threatening illness 
14. History of drug overdose, attempted suicide or significant active mental illness 
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15. Pregnant or breastfeeding women 
16. Women of childbearing age not taking contraception 
17. Use of prohibited medications (anticoagulants, phosphodiesterase 5’ inhibitors, 
macrolides, ketoconazole, itraconazole, omeprazole) 
18. Creatinine clearance < 25ml/min 
19. Hepatic impairment 
20. Current enrolment in another Clinical Trial of Investigational Medicinal Product 
(CTIMP) 
 
Randomization  
Baseline information is entered on a password-protected website 
(https://nottingham.ac.uk/~nszwww/prev-svd/). Once checked and complete, a computer 
algorithm randomises participants at a 1:1:1:1 ratio to a study group. Randomisation is 
minimised on age ≤/>70 years, SVD severity on brain scanning (SVD score ≤/>2)(22), 
systolic blood pressure ≤/>140mmHg and time after stroke ≤/>100 days. 
 
Intervention  
The starting dose for cilostazol is 50mg twice daily, increasing to 100mg twice daily (target 
dose). The starting dose of ISMN is 25mg once daily increasing to 25mg twice daily (target 
dose). Participants allocated to both drugs aim to attain the same target doses as for the 
drugs alone (dose schedules in Supplementary Information). Unused tablets are returned to 
Pharmacy for counting and destruction at the end of the 11-week period. 
 
Primary outcome  
The proportion of participants achieving target dose assessed by alternate weeks structured 
questionnaire, supplemented by diary and Pharmacy tablet count. 
 
Secondary outcomes  
1) Symptoms (headache, nausea, diarrhoea, vomiting, bleeding) recorded by structured 
questionnaire.  
2) Safety (systemic or intracranial bleeding, recurrent vascular events, death).  
3) Blood pressure.  
4) Platelet function (P-selectin flow cytometry)(23)  
5) Systemic arterial stiffness (pulse wave velocity and pulse wave analysis using the 
SphygmoCor tonometry device. 
6) In a subgroup recruited in Edinburgh, cerebrovascular reactivity (CVR)(7) in white matter 
and cerebrospinal fluid and blood pulsatility, assessed using MRI. Acquisition details are 
provided in the Supplementary Information. 
 
Blinding:  
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The processing and analysis of CVR, platelet function, pulse wave velocity, blood pressure 
and all tablet counts, study questionnaires and compliance data will be performed blind to 
treatment allocation. Apart from the study research fellow and research nurse, other staff 
performing the above assessments will not be aware of the treatment allocation, particularly 
during image analysis, blood tests and follow-up data analysis. When talking to participants, 
the tablets will only be referred to as ‘A’ or ‘B’ to facilitate patients’ understanding of 
procedures. 
 
Data Monitoring Committee 
An independent data monitoring committee (DMC) is established, chair Prof Colin Baigent 
(Oxford).  
 
Sample size  
A sample size of 55 provides 80% power (significance 0.05) to detect  a difference of 90% 
versus 55% (ie an absolute difference of 35%) between those reaching target doses on one 
drug versus both drugs; ie we expect that 35% fewer patients will tolerate both versus one of 
the two drugs and the sample size is set to be able to detect that difference. For CVR, 
lacunar stroke patients have impaired middle cerebral artery vasoreactivity on transcranial 
Doppler ultrasound with an effect size of 25%, standard deviation (SD) of 40% (4). Little data 
exist on CVR measured by blood oxygen level dependent (BOLD) MRI in lacunar stroke(7). 
The 40 participant sample in Edinburgh will allow detection of a relative difference in CVR of 
25% (4% vs 3% signal; with estimated common SD of 40%) between no treatment and 
target dose of both drugs, significance 0.05 and power 0.80.  
Allowing for losses, 60 participants will be recruited in total. 
 
Analyses 
Image processing: Structural MR images will be scored for SVD lesion burden using 
validated scales(24) and processed to generate tissue segmentation maps using validated 
software(25). CVR (% signal change/mmHg CO2) will be determined by multiple linear 
regression of the BOLD MRI signal time course, with the end-tidal CO2 and time (to account 
for scanner drift) as regressors, for specific tissue regions for comparison of trial drugs and 
doses.  
Statistical: We will compare cilostazol vs. none, ISMN vs. none, and cilostazol and ISMN 
given immediately vs. both given after a delay (the delayed start provides a drug-free control 
period; having two groups that both get both drugs compares drug initiation with one vs. the 
other drug). We will compare symptoms, blood pressure, arterial stiffness, platelet function 
and CVR by treatment allocation. The primary outcome (proportion of participants achieving 
target dose) will be assessed using binary logistic regression with adjustment for 
minimisation factors; age, SVD score, systolic blood pressure and time from stroke to 
randomisation (days). The secondary outcomes will be assessed using binary logistic 
regression for binary variables, multiple linear regression for continuous variables and Cox 
proportional hazards regression for variables which have a time-until-event component. As 
data are collected over an eleven- week period, time trends will also be examined. 
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Data tables and figures summarising the main planned comparisons are provided in the 
Supplementary Information. 
 
Study organization and funding 
The study is funded by The Alzheimer’s Society and will be performed in the Centre for 
Clinical Brain Sciences and Edinburgh Clinical Trials Unit, University of Edinburgh and the 
Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham.  
 
Discussion:  
Intensive assessment 
LACI-1 follows participants intensively over 11 weeks including three research clinic visits (to 
assess BP, platelet function, arterial stiffness, CVR and symptoms) and five telephone 
follow-ups (to assess side-effects and guide dose escalation). The intense follow-up 
provides data on dose escalation and safety to inform a future larger, pragmatic, phase III 
trial with less frequent follow-up.  
 
PROBE design 
The PROBE design blinds the main study outcomes whilst maintaining feasibility of dose 
escalation. A double-blind design proved to be impractical as there is no matching placebo 
for either study drug. Furthermore, masking by over-encapsulation was impractical and 
prohibitively expensive when combined with dose escalation. Complicated arrangements for 
dispensing multiple bottles of study drug, with different dose combinations, were required, 
with high risk of reduced compliance, confusion and incorrect medication. The PROBE 
design is well established(26) and the study has been designed and staffed appropriately to 
maintain investigator blinding at the point of outcome assessment.  
 
Factorial design 
The factorial design compares each drug to no drug and also combination therapy to no 
therapy. The ‘delayed start’ group provides a modified ‘no-drug’ control group as these 
participants do not receive medication for the first three weeks after randomisation so are not 
on any medication at the second visit (week 3). They start medication following the week 3 
visit, creating a more efficient design, as all participants receive study drug and tests the 
effect of which drug is commenced first in the combination groups (Supplementary 
Information). Randomisation using minimisation increases statistical power. 
 
Dose Escalation 
The common side effects of both study drugs (ISMN: headache; cilostazol: headache, 
palpitations) are usually encountered soon after starting the medication. Slow dose 
escalation at treatment initiation is widely used to lessen these side-effects. However, 
evidence for this comes from a single non-randomised study(27) and  personal experience. 
Dose escalation of dipyridamole, a phosphodiesterase 5’ inhibitor with a similar 
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pharmacodynamics profile to cilostazol, did not reduce headache in a blinded randomised 
comparison(28). LACI-1 will provide objective evidence on the frequency of common 
inception side effects to inform a larger pragmatic trial at up to 20 sites to select the regimen 
that best balances simplicity with tolerability and compliance. 
 
Mechanistic Endpoints 
Stroke recurrence, whilst a significant problem following lacunar stroke, occurs relatively 
infrequently and late, whilst radiological progression of SVD is relatively slow(29). Hence 
large trials with long follow-up periods are required to detect treatment effects. To enhance 
information on pharmacological effects of cilostazol and ISMN at these doses, we will use 
mechanistic vascular function endpoints (Fig. 3):  changes in CVR measured using 
hypercapnic challenge BOLD MRI scans(7), and changes in arterial, venous and 
cerebrospinal fluid flow characteristics measured using phase-contrast MRI; improvement in 
systemic vascular stiffness using pulse wave velocity (SphygmoCor tonometry device); and 
alteration in platelet function will test effects on platelet activation and provide safety data 
(30).  
 
Bleeding 
Cilostazol (but not ISMN) has a low risk of bleeding, a potential interaction with the 
background antiplatelet medication that patients will be taking. One of the aims of LACI-1 is 
to assess whether bleeding is enhanced when patients take these combinations of 
antiplatelet agents. 
 
Summary and conclusions. 
LACI-1 will provide data on tolerability, safety and surrogate efficacy markers for cilostazol 
and ISMN in patients with lacunar stroke, and will inform the design of a larger pragmatic 
phase III study. 
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Figures 
 
Figure 1. Meta-analysis of trials of cilostazol for secondary stroke prevention(31-35).  
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Figure 2: Flow chart of study procedures  
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Figure 3: Mechanistic endpoints (‘intermediary outcomes’) assessing brain and systemic 
vascular function in response to cilostazol and isosorbide mononitrate. A) Brain – CVR MRI 
scans. The dark blue areas indicate the least reactive tissues, the bright red areas are the 
most reactive tissues. B) Carotid and vertebral arteries – phase contrast MRI scan, which 
also measures intracranial arterial, venous sinus and CSF flow. C) Systemic arteries -Aortic 
and Radial artery pressure waveforms and pulse wave velocity. D) Platelet function is 
assessed with P-Selectin flow cytometry.	
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S1 Drug dosing tables 
Group 1: Patients randomised to Isosorbide Mononitrate alone 
 
 Group 1 Dosing Regime 
Week 
ISMN 
Morning Evening 
1 Nil 25mg 
2 25mg 25mg 
3 25mg 25mg 
4 25mg 25mg 
5 25mg 25mg 
6 25mg 25mg 
7 25mg 25mg 
8 25mg 25mg 
9 25mg Nil 
10 Nil Nil 
11 Nil Nil 
 
Group 2: Patients randomised to cilostazol alone 
 
Group 2 Dosing Regime 
Week 
Cilostazol 
Morning Evening 
1 50mg 50mg 
2 100mg 50mg 
3 100mg 100mg 
4 100mg 100mg 
5 100mg 100mg 
6 100mg 100mg 
7 100mg 100mg 
8 100mg 100mg 
9 50mg 50mg 
10 Nil Nil 
11 Nil Nil 
18	
	
Group	 3:	 Patients randomised to both Isosorbide Mononitrate and Cilostazol - start 
immediately – ISMN first		
	
Group 3 Dosing Regime 
Week 
Isosorbide Mononitrate Cilostazol 
Morning Evening Morning Evening 
1 Nil 25mg Nil Nil 
2 25mg 25mg Nil Nil 
3 25mg 25mg 50mg 50mg 
4 25mg 25mg 100mg 50mg 
5 25mg 25mg 100mg 100mg 
6 25mg 25mg 100mg 100mg 
7 25mg 25mg 100mg 100mg 
8 25mg 25mg 100mg 100mg 
9 25mg Nil 50mg 50mg 
10 Nil Nil Nil Nil 
11 Nil Nil Nil Nil 
	
Group	4:	Patients randomised to both Isosorbide Mononitrate and Cilostazol - delayed start 
– cilostazol first - Group 4: 
	
Group 4 Dosing Regime 
Week 
Isosorbide Mononitrate Cilostazol  
Morning Evening Morning Evening 
1 Nil Nil Nil Nil 
2 Nil Nil Nil Nil 
3 Nil Nil Nil Nil 
4 Nil Nil 50mg 50mg 
5 Nil Nil 100mg 50mg 
6 Nil 25mg 100mg 100mg 
7 25mg 25mg 100mg 100mg 
8 25mg 25mg 100mg 100mg 
9 25mg Nil 50mg 50mg 
10 Nil Nil Nil Nil 
11 Nil Nil Nil Nil 
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S2 Data tables for statistical analysis 
Table 1. Baseline characteristics. Data are number (%), median [interquartile range] or 
mean (standard deviation). 
Variable  All  Both 
delayed  
ISMN  Cilostazol Both 
immediate 
Patients (%)      
Age (years)      
Sex, female (%)      
Onset to randomisation (days)      
Scan type, MRI (%)      
Visible acute stroke lesion MRI 
(%) 
     
Lesion visible on DWI (%)      
Lesion visible on FLAIR (%)      
Side of brain, left (%)      
SVD score MRI ( /4)      
   ≥1 Lacune (%)      
   ≥1 Microbleeds (%)      
   Perivascular spaces (%)      
WMH Fazekas MRI      
Visible acute stroke lesion CT (%)      
Side of brain left (%)      
SVD score CT ( /2      
  ≥1 Lacune (%)      
  WMH Score      
  Atrophy       
Systolic BP (mmHg)      
Diastolic BP (mmHg)      
Arm used for BP, left (%)       
Past medical history (%)      
Treated hypertension       
Treated hyperlipidaemia       
Diabetes       
Atrial fibrillation       
Ipsilateral carotid stenosis >50%      
Peripheral arterial disease      
Heart failure      
Angina      
Myocardial infarction      
Previous stroke       
Previous TIA      
Stroke in immediate family      
Smoking       
Alcohol intake [upw]      
Additional salt (%)       
mRS – pre-stroke [/6]      
mRS – baseline [/6]      
Current NIHSS      
MoCA (/30)      
TMT Part A (secs)       
TMT test Part A (points)      
TMT Part B – (secs)      
TMT Part B – (points)      
National adult reading test (error 
score) 
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mRs, modified Rankin Score; NIHSS, National Institutes of Health Stroke Scale; MoCA, Montreal Cognitive 
Assessment; TMT, Trail Making Test. 
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S2, Table 2. Tablet compliance. Note, here ‘full dose’ is defined as achieving the whole dose 
prescribed for that time period (e.g. 25mg/day for week 1 of ISMN); ‘partial dose’ is defined 
as achieving part of the dose prescribed for that time period (e.g. 25mg only on alternate 
days for ISMN). 
Variable  All  Both 
delayed  
ISMN  Cilostazol Both 
immediate  
Week 1 (telephone)      
Adherence full dose (%)      
Adherence partial dose (%)      
No. doses missed      
Week 2 (telephone)      
Adherence full dose (%)      
Adherence partial dose (%)       
No. doses missed (if any)      
Week 3 (clinic)       
Adherence full dose (%)      
Adherence partial dose (%)      
No. doses missed (if any)       
Week 5 (telephone)      
Adherence full dose (%)      
Adherence partial dose (%)       
No. doses missed (if any)      
Week 7 (telephone)      
Adherence full dose (%)      
Adherence partial dose (%)      
No. doses missed (if any)       
Week 8 (clinic)      
Adherence full dose (%)      
Adherence partial dose (%)      
No. doses missed (if any)       
 
 
